Showing results (1-10 of 19) with videos related to

Sort By:
Pageof 2
American Journal of Hematology|January 4, 2021
New regimens and directions in the management of newly diagnosed multiple myelomaSusan Bal, Smith Giri, Kelly N Godby, et al.
Annals of Hematology|February 9, 2022
Revisiting the impact of immunoglobulin isotypes in multiple myelomaSusan Bal, Smith Giri, Kelly N Godby, et al.
American Journal of Hematology|August 24, 2023
Teclistamab in patients with multiple myeloma and impaired renal functionLaura Joiner, Susan Bal, Kelly N Godby, et al.
British Journal of Haematology|July 6, 2018
Second primary malignancy after multiple myeloma-population trends and cause-specific mortalityLuciano J Costa, Kelly N Godby, Saurabh Chhabra, et al.
British Journal of Haematology|January 31, 2024
Subsequent therapy and outcomes in patients with newly diagnosed multiple myeloma experiencing disease progression after quadruplet combinationsGayathri Ravi, Susan Bal, Laura Joiner, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|February 8, 2018
Phase 1/2 Trial of Carfilzomib Plus High-Dose Melphalan Preparative Regimen for Salvage Autologous Hematopoietic Cell Transplantation Followed by Maintenance Carfilzomib in Patients with Relapsed/Refractory Multiple MyelomaLuciano J Costa, Heather J Landau, Saurabh Chhabra, et al.
Journal of Geriatric Oncology|December 20, 2021
Pre-treatment neutrophil to lymphocyte ratio as a biomarker of frailty and predictor of survival among older adults with multiple myelomaSmith Giri, Sumit Dahal, Susan Bal, et al.
Translational Oncology|September 1, 2023
Evaluation of a semi-automated approach for FDG PET image analysis for routine clinical application in patients with multiple myelomaTyler J Wellman, Sarah R Mudd, Kelly N Godby, et al.
British Journal of Haematology|February 16, 2026
Validation of the 2025 IMS/IMWG risk classification in patients with newly diagnosed multiple myeloma treated with quadruplets and autologous stem cell transplantPriyanka Venkatesh, Gayathri Ravi, Binod Dhakal, et al.
Ejhaem|August 21, 2023
Humoral immune reconstitution following therapy with daratumumab, carfilzomib, lenalidomide, and dexamethasone (Dara-KRd), autologous hematopoietic cell transplantation, and measurable residual disease-response-adapted treatment cessationRebecca W Silbermann, Timothy Martin Schmidt, Susan Bal, et al.
Pageof 2